Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC By Ogkologos - April 28, 2026 1 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Get to Know CaringBridge June 3, 2021 Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer March 15, 2022 Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 Load more HOT NEWS ESMO Highlights Key Issues for Patients with Cancer and Their Carers... EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide What to Know About Using Activated Charcoal During Cancer Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced...
